Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)

v3.23.1
Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Earnings Per Share                
Net earnings, including noncontrolling interest $ 70,218 $ 50,005 $ 89,734 $ 60,144 $ 72,059 $ 68,981 $ 209,958 $ 201,184
Less net earnings (loss) attributable to noncontrolling interest       (595)     179 (9,343)
Net earnings attributable to Bio-Techne 70,218     60,739     209,779 210,527
Income allocated to participating securities (16)     (25)     (52) (95)
Income available to common shareholders $ 70,202     $ 60,714     $ 209,727 $ 210,432
Weighted-average shares outstanding - basic (in shares) 157,311     157,087     157,071 156,899
Earnings per share - basic (in shares) $ 0.45     $ 0.39     $ 1.34 $ 1.34
Income available to common shareholders $ 70,202     $ 60,714     $ 209,727 $ 210,432
Dilutive effect of stock options and restricted stock units (in shares) 4,304     6,787     4,697 7,393
Weighted-average common shares outstanding - diluted (in shares) 161,615     163,874     161,768 164,292
Earnings per share - diluted (in shares) $ 0.43     $ 0.37     $ 1.30 $ 1.28